Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has announced the expansion of its ongoing clinical trials for Netherton Syndrome (NS) to include two additional sites in the United Kingdom. The sites, Great Ormond Street Hospital and St. Thomas’ Hospital, both located in London, are recognized centers of excellence for treating Netherton Syndrome patients.
A Principal Investigator (PI) has been appointed for the UK studies, and a Clinical Research Organization has been engaged to manage the trials. These sites, along with a previously announced site in Saudi Arabia, will operate under Quoin’s Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).
Quoin is also in advanced stages of preparation for opening additional clinical trial sites in several other Western European countries and is concluding a feasibility study in multiple Eastern European countries. These territories have available cohorts of patients with Netherton Syndrome, facilitating quicker enrollment.
QRX003 Clinical Trials
Quoin is currently conducting two clinical trials evaluating QRX003, a topical lotion, for the treatment of Netherton Syndrome, a rare, inherited genetic disease characterized by skin inflammation and barrier defects. The primary aim of these trials is to assess the safety and efficacy of QRX003 in reducing the severity of Netherton Syndrome symptoms.
Dr. Michael Myers, CEO of Quoin, stated, “We are very pleased to announce yet another exciting development for our ongoing clinical studies. This further international expansion underscores our determination and commitment to complete enrollment into both studies as rapidly as possible with a view to potentially delivering the first approved treatment to this underserved patient population.”
About Netherton Syndrome
Netherton Syndrome is a rare, autosomal recessive disorder caused by mutations in the SPINK5 gene, which encodes the LEKTI protein, a serine protease inhibitor involved in skin barrier function. The disease is characterized by chronic skin inflammation, scaling, and ichthyosis, often leading to significant morbidity and reduced quality of life. Current treatments are largely supportive, focusing on symptom management and skin hydration.
Quoin's Broader Pipeline
Quoin Pharmaceuticals is focused on developing and commercializing therapeutic products for rare and orphan diseases. Their pipeline includes five products in development targeting indications such as Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa.
